Payment overview · 2025
General Payments
$1,510.37
81 reported records · 22 companies
Healthcare provider profile · identity verified
Sanjay Kumar Choudhary, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIDDLEBURG HEIGHTS, OH · NPI 1407858228
Verified facts
What the public records show
CMS Open Payments records show Sanjay Kumar Choudhary, MD received $1,510.37 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Farxiga, Ozempic, Rexulti, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auvelity by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $233.99 | 15.5% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.99 | 12.9% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $156.05 | 10.3% | 15 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $143.82 | 9.5% | 1 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $138.31 | 9.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $82.71 | 5.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.33 | 5.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.33 | 4.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.75 | 3.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.59 | 3.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.56 | 3.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.62 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.86 | 2.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.18 | 2.3% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $35.17 | 2.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.45 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.15 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.33 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.67 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.28 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.23 | 1.1% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $16.00 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,510.37 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $170.30 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $156.05 | 15 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $143.82 | 1 | 2025 |
Source payment records
|
|||||
| iTIND System Normalized: itind system |
Device | Olympus America Inc. | $138.31 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.59 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.27 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $82.71 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.69 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.48 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.36 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.75 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.59 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.91 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.18 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 86 |
| Losartan Potassium | Losartan Potassium | 162 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 34 |
| Alprazolam | Alprazolam | 142 | 26 |
| Lisinopril | Lisinopril | 137 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 33 |
| Metformin Hcl | Metformin Hcl | 120 | 22 |
| Furosemide | Furosemide | 119 | 28 |
| Gabapentin | Gabapentin | 118 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 33 |
| Potassium Chloride | Potassium Chloride | 78 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 14 |
| Azithromycin | Azithromycin | 77 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 16 |
| Eliquis | Apixaban | 71 | 15 |
| Omeprazole | Omeprazole | 67 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 50 | 15 |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 16 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Prednisone | Prednisone | 45 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 14 |
| Finasteride | Finasteride | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 30 |
| Levofloxacin | Levofloxacin | 37 | 16 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 14 |
| Haloperidol | Haloperidol | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Nystatin | Nystatin | 27 | 12 |
| Ozempic | Semaglutide | 27 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,510.37 · 81 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GIMOTI, GVOKE HYPOPEN, KRYSTEXXA, LEQVIO, OTEZLA, Ozempic, PROVENGE, QULIPTA, RELISTOR, REPATHA, REXULTI, SPRAVATO, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, ZENPEP, iTIND System | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error